Clinical Trials

Entasis, GARP to start phase 3 trials of drug-resistant gonorrhea antibiotic

Entasis Therapeutics and Global Antibiotic Research and Development Partnership (GARDP) will initiate pivotal trials of oral antibiotic zoliflodacin (ETX0914) being developed to treat drug-resistant gonorrhea.

Prothena commences phase 2 trial of Parkinson’s disease drug

Prothena has reported that the first patient has been enrolled in PASADENA, a global Phase 2 study of PRX002/RG7935 in patients with early Parkinson's disease.

Zealand Pharma starts phase 3 trial of dasiglucagon to treat severe hypoglycemia in diabetes

Zealand Pharma has started a multinational Phase 3 clinical trial of dasiglucagon in four countries (Austria, Germany, Canada and the US).

Daiichi Sankyo’ pain drug mirogabalin meets primary end point in Neucourse phase 3 study

Daiichi Sankyo's pain drug mirogabalin has showed mixed results in phase 3 global clinical development program.

bluebird unveils topline interim data from Starbeam study of Lenti-D in CALD

bluebird bio has released topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating its investigational gene therapy Lenti-D in under-18 boys with cerebral adrenoleukodystrophy (CALD).

Roche’s emicizumab shows substantial reduction in bleeds in phase III studies

Roche’s haemophilia A drug emicizumab has showed a significant effect in the phase III Haven 1 and Haven 2 studies.

Novartis’ heart drug canakinumab meets primary endpoint in phase III study

Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study.

Pfizer initiates phase 1 study of streptococcus vaccine

Pfizer has commenced a phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine for the prevention of Group B Streptococcus (GBS) infection.

Centrexion’s pain drug CNTX-4975 yields positive results in phase 2b knee osteoarthritis trial

Centrexion Therapeutics reported positive 6-month efficacy data from the Phase 2b TRIUMPH trial demonstrating durable response of CNTX-4975 for treatment of chronic pain associated with knee osteoarthritis.